No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.

No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.

Preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) reduced HIV acquisition in the iPrEx trial among men who have sex with men and transgender women. Self-reported sexual risk behavior decreased overall, but may be affected by reporting bias. We evaluated potent...

Full description

Bibliographic Details
Main Authors: Julia L Marcus, David V Glidden, Kenneth H Mayer, Albert Y Liu, Susan P Buchbinder, K Rivet Amico, Vanessa McMahan, Esper Georges Kallas, Orlando Montoya-Herrera, Jose Pilotto, Robert M Grant
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3867330?pdf=render

Internet

http://europepmc.org/articles/PMC3867330?pdf=render

Similar Items